18:07 , Aug 29, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms; drug properties

TECHNOLOGY: Peptides; pharmacokinetics/pharmacodynamics; physicochemical properties A palmitoylated heptapeptide could be used to enhance the stability and serum half-lives of therapeutic peptides. The heptapeptide consisted of an amino acid sequence containing four glutamic acid residues for...
22:23 , Jul 20, 2017 |  BC Extra  |  Preclinical News

Team develops conjugation strategy for longer-lived peptides

In a Nature Communications paper , a research team led by Christian Heinis at the Ecole Polytechnique Federale de Lausanne (EPFL) showed that conjugating a peptide-fatty acid construct to therapeutic peptides could extend their half-lives...
07:00 , Apr 2, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Factor XIIa; β-amyloid 42 (Aβ42)

Neurology INDICATION: Alzheimer's disease (AD) Studies in patient samples and mice suggest systemic Factor XIIa inhibition could help treat AD. In serum from AD patients, levels of Factor XIIa and markers of kallikrein - which...
08:00 , Feb 27, 2014 |  BC Innovations  |  Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
08:00 , Jan 17, 2005 |  BioCentury  |  Emerging Company Profile

Catalyst: Protease platform

As one of the largest gene families, composing about 2.5% of the human genome, it is hard to find a biological or pathological process in which proteases don't play a role. This makes them a...
08:00 , Nov 1, 2004 |  BioCentury  |  Product Development

Treating HAE

Treating HAE In normal patients, C1 esterase inhibitor can normalize inflammation by intervening to slow formation of prekallikrien from Factor XIIa or by inhibiting conversion of HMW-kininogen. Kallikrein mediates the release of bradykinin from precursors....